Meeting
2019 ASCO Annual Meeting
First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.
Authors
David Planchard
Gustave Roussy, Villejuif, France
David Planchard , Byoung Chul Cho , Jhanelle Elaine Gray , Luis G. Paz-Ares , Mustafa Ozguroglu , Augusto E. Villegas , Davey B. Daniel , David Vicente , Shuji Murakami , Rina Hui , Takayasu Kurata , Alberto Chiappori , Ki Hyeong Lee , Maike De Wit , Yu Gu , Catherine Wadsworth , Phillip A. Dennis , Scott Joseph Antonia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9054)
DOI
10.1200/JCO.2019.37.15_suppl.9054
Abstract #
9054
Poster Bd #
377
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
First Author: Mustafa Özgüroğlu
Poster
2023 ASCO Annual Meeting
A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC).
First Author: Luis G. Paz-Ares
Poster
2023 ASCO Annual Meeting
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.
First Author: Benjamin Besse
Poster
2022 ASCO Annual Meeting
Effect of durvalumab in patients with unresectable stage 3 non–small cell lung cancer post-chemoradiotherapy.
First Author: Aswani Thurlapati